The DOI matches its Crossref record.
A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine
Abstract
BACKGROUND: Although many whole-cell vaccines have been effective in preventing pertussis, these vaccines are difficult to standardize and can produce side effects. In Sweden, pertussis became endemic during the 1970s despite vaccination. Because of its limited efficacy, the Swedish-made whole-cell vaccine was withdrawn in 1979. METHODS: To evaluate the efficacy of an acellular vaccine consisting of pertussis toxin inactivated by hydrogen peroxide (pertussis toxoid), we conducted a randomized, double-blind, placebo-controlled trial in Sweden. Infants were vaccinated with either diphtheria and tetanus toxoids alone (DT toxoids, 1726 infants) or diphtheria, tetanus, and pertussis toxoids (DTP toxoids, 1724 infants) at 3, 5, and 12 months of age. RESULTS: There were no serious reactions. With the pertussis vaccine there were slightly more local reactions than with the DT toxoids alone, but the rates of postvaccination fever were the same. The main period of surveillance, which began 30 days after the third vaccination, continued for a median of 17.5 months. There were 312 cases of pertussis (72 in the DTP-toxoids group and 240 in the DT-toxoids group) that met the clinical criterion (paroxysmal cough lasting > or = 21 days) and laboratory criteria for pertussis as defined by the World Health Organization. The efficacy of this acellular vaccine was 71 percent (95 percent confidence interval, 63 to 78 percent). The recipients of DTP toxoids who had pertussis had cough of shorter duration than the recipients of DT toxoids, and fewer had whooping and vomiting. The vaccine efficacy after two doses was 55 percent (95 percent confidence interval, 12 to 78 percent), on the basis of 14 cases in the DTP-toxoids group and 31 in the DT-toxoids group that met the definition of the World Health Organization. CONCLUSIONS: A pharmacologically inert, acellular pertussis-toxoid vaccine that is easily standardized is safe and confers substantial protection against pertussis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aluminum compounds as vaccine adjuvants
Gupta, R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00008-8 · Cited by 623
Stehr, K., Cherry, J. D., Heininger, U., Schmitt-Grohé, S., Überall, M., Laussucq, S., Eckhardt, T., Meyer, M., Engelhardt, R., Christenson, P., et al. (1998) · Pediatrics · doi:10.1542/peds.101.1.1 · Cited by 511
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
Cherry, J. D., Gornbein, J., Heininger, U., & Stehr, K. (1998) · Vaccine · doi:10.1016/s0264-410x(98)00226-6 · Cited by 434
Design and Analysis of Vaccine Studies
Halloran, M. E., Longini, I. M., & Struchiner, C. J. (2010) · Statistics for Biology and Health · doi:10.1007/978-0-387-68636-3 · Cited by 326
Efficacy of Acellular Pertussis Vaccine in Early Childhood After Household Exposure
Schmitt, H.-J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250041024 · Cited by 272
Metadata
- Authors
- Trollfors, B., Taranger, J., Lagergård, T., Lind, L., Sundh, V., Zackrisson, G., Lowe, C. U., Blackwelder, W., & Robbins, J. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-19
- Volume
- 333
- Issue
- 16
- Pages
- 1045-1050
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2340710149
- Cited by
- 291
- References
- 0
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine. https://app.cochat.ai/papers/10.1056/nejm199510193331604
- The paper
- Trollfors, B., Taranger, J., Lagergård, T., Lind, L., Sundh, V., Zackrisson, G., Lowe, C. U., Blackwelder, W., & Robbins, J. B. (1995). A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine. New England Journal of Medicine. https://doi.org/10.1056/nejm199510193331604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.